NASDAQ:ELGX - Endologix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.75 -0.08 (-9.64 %)
(As of 01/23/2019 08:37 AM ET)
Previous Close$0.8299
Today's Range$0.7499 - $0.8447
52-Week Range$0.59 - $6.72
Volume1.01 million shs
Average Volume792,641 shs
Market Capitalization$77.59 million
P/E Ratio-1.56
Dividend YieldN/A
Beta0.51
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions which allows physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. The company offers its EVAR products under Ovation, Powerlink System, IntuiTrak, AFX, VELA Proximal Endograft brand names; and EVAS products under the Nellix EVAS system brand name. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Receive ELGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ELGX
CUSIP29266S10
Phone949-595-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$181.16 million
Book Value$0.90 per share

Profitability

Net Income$-66,400,000.00

Miscellaneous

Employees675
Market Cap$77.59 million
OptionableOptionable

Endologix (NASDAQ:ELGX) Frequently Asked Questions

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

How were Endologix's earnings last quarter?

Endologix, Inc. (NASDAQ:ELGX) released its quarterly earnings data on Thursday, November, 1st. The medical instruments supplier reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. The medical instruments supplier earned $34.76 million during the quarter, compared to the consensus estimate of $33.04 million. Endologix had a negative net margin of 41.19% and a negative return on equity of 89.31%. The firm's revenue for the quarter was down 24.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.17) EPS. View Endologix's Earnings History.

When is Endologix's next earnings date?

Endologix is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for Endologix.

What guidance has Endologix issued on next quarter's earnings?

Endologix issued an update on its first quarter 2019 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $35-35 million, compared to the consensus revenue estimate of $31.93 million.Endologix also updated its FY 2018 guidance to EPS.

What price target have analysts set for ELGX?

5 brokers have issued 12-month price objectives for Endologix's shares. Their predictions range from $3.00 to $4.00. On average, they anticipate Endologix's share price to reach $3.40 in the next year. This suggests a possible upside of 353.3% from the stock's current price. View Analyst Price Targets for Endologix.

What is the consensus analysts' recommendation for Endologix?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endologix.

What are Wall Street analysts saying about Endologix stock?

Here are some recent quotes from research analysts about Endologix stock:
  • 1. According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (1/21/2019)
  • 2. BTIG Research analysts commented, "and Endologix reported its Q3 with few surprises given the preannouncement at the early October analyst day. Total revenue of $34.8M came in slightly above the preannounced range. Management said it felt AFX performed well in the US and Latin America, and that Ovation had a nice quarter in the US and Europe. The company reiterated its plan to go deeper into larger accounts and noted that this allowed gross margins to increase in the quarter while spend decreased ~7%. We believe ELGX offers a versatile slew of EVAR options, has a chance to be acquired, and has a shot to show premium data and/or a mortality benefit from the Nellix EVAS2 trial in 2020. We reiterate our Buy." (11/4/2018)

Has Endologix been receiving favorable news coverage?

Headlines about ELGX stock have been trending somewhat positive recently, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Endologix earned a news impact score of 1.4 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the near term.

Who are some of Endologix's key competitors?

Who are Endologix's key executives?

Endologix's management team includes the folowing people:
  • Mr. John Onopchenko, CEO & Director (Age 60)
  • Mr. Vaseem Mahboob, Chief Financial Officer (Age 50)
  • Dr. Michael V. Chobotov, Chief Technology Officer (Age 58)
  • Mr. Jeffrey S. Brown, Chief Operations Officer
  • Mr. Jeremy B. Hayden, Gen. Counsel (Age 49)

How do I buy shares of Endologix?

Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endologix's stock price today?

One share of ELGX stock can currently be purchased for approximately $0.75.

How big of a company is Endologix?

Endologix has a market capitalization of $77.59 million and generates $181.16 million in revenue each year. The medical instruments supplier earns $-66,400,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Endologix employs 675 workers across the globe.

What is Endologix's official website?

The official website for Endologix is http://www.endologix.com.

How can I contact Endologix?

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]


MarketBeat Community Rating for Endologix (NASDAQ ELGX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  384 (Vote Outperform)
Underperform Votes:  377 (Vote Underperform)
Total Votes:  761
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe ELGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by MarketBeat.com Staff

Featured Article: What is Liquidity?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel